Skip to main content
. 2022 Nov 5;197(1):161–175. doi: 10.1007/s10549-022-06732-y

Fig. 4.

Fig. 4

Percentage change in the 3-week moving average of the number of patients (group 2) starting a neo-adjuvant chemotherapy, b neo-adjuvant endocrine therapy, c neo-adjuvant targeted therapy, d surgery, e breast-conserving surgery, f mastectomy, g mastectomy with immediate breast reconstruction, h adjuvant chemotherapy, i adjuvant endocrine therapy, j adjuvant targeted therapy, or k adjuvant radiotherapy. 3-week moving average was calculated over the week of interest and the two weeks preceding this week Percentage change calculated as the percentage of the corresponding three-week moving average of 2018/2019